The tweet was deleted by the author.
But we saved everything 🙂.
Biogen has announced new Phase 1b clinical trial results for its investigational spinal muscular atrophy (SMA) medicine at the 2026 MDA Conference hosted by the Muscular Dystrophy Association.
The company also revealed details of its Phase 3 clinical development program for the treatment, underscoring its commitment to advancing therapies for SMA. The findings provide insight into the drug's safety and efficacy in early-stage studies, while the upcoming Phase 3 program aims to further assess the medicine's potential. Details about the timeline and enrollment for the Phase 3 trial are expected in future updates.
View post on X Loading...
The latest findings from Biogen’s SMA trials build upon momentum observed at the 2026 MDA Conference, where the company previously outlined significant progress in its spinal muscular atrophy research pipeline. For a comprehensive overview of those earlier developments, refer to the detailed analysis of Biogen’s SMA data presented during the event.